{"url_path":"/sec/crvo/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-017236-index.html","accession_number":"0001437749-26-017236","cik":"0001053691","ticker":"CRVO","issuer_name":"CervoMed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-017236-index.html","primary_entity_key":"0001053691","primary_entity_name":"CervoMed Inc."},"word_count":585,"has_tables":true,"body_markdown":"crvo20260331c_10q.htm\n\nQ1\n2026\n--12-31\nfalse\n0001053691\nfalse\nfalse\nfalse\nfalse\n1\n10\n2\n0\n1\n4\n10\n0\n0\n0\n0\n0\n10\n0\n0\n0\n0\n\n00010536912026-01-012026-03-31\nthunderdome:item\niso4217:USD\n0001053691us-gaap:OperatingSegmentsMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:OtherResearchAndDevelopmentCostsMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:OtherResearchAndDevelopmentCostsMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:StockBasedCompensationMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:StockBasedCompensationMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:PersonnelCostsMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:PersonnelCostsMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:OtherClinicalAndNonclinicalMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:OtherClinicalAndNonclinicalMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:RecoveryAfterStrokeMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:RecoveryAfterStrokeMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:FrontotemporalDisordersMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:FrontotemporalDisordersMember2026-01-012026-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:DementiaWithLewyBodiesMember2025-01-012025-03-31\n0001053691us-gaap:OperatingSegmentsMembercrvo:DementiaWithLewyBodiesMember2026-01-012026-03-31\nxbrli:pure\n0001053691crvo:StockOptionVestingTermsAsImprobableToProbableMembersrt:ChiefOperatingOfficerMember2026-01-012026-03-31\nutr:Y\n0001053691us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001053691us-gaap:EmployeeStockOptionMember2026-03-31\n0001053691us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n00010536912026-03-31\niso4217:USDxbrli:shares\nxbrli:shares\n00010536912025-01-012025-12-31\n00010536912025-12-31\n00010536912025-01-012025-03-31\n0001053691crvo:GeneralAndAdministrativeMember2025-01-012025-03-31\n0001053691crvo:GeneralAndAdministrativeMember2026-01-012026-03-31\n0001053691crvo:ResearchAndDevelopmentMember2025-01-012025-03-31\n0001053691crvo:ResearchAndDevelopmentMember2026-01-012026-03-31\n0001053691crvo:The2025EquityPlanMember2026-03-31\nutr:M\n0001053691crvo:InducementOptionsMember2024-01-012024-12-31\n0001053691crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember2026-03-31\n0001053691us-gaap:EmployeeStockOptionMembercrvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-03-31\n0001053691us-gaap:EmployeeStockOptionMembercrvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember2026-01-012026-03-31\n0001053691crvo:EquityIncentivePlan2015Member2025-01-01\n0001053691crvo:EquityIncentivePlan2015Member2026-01-012026-03-31\n0001053691crvo:May2025AtthemarketOfferingMember2026-01-012026-03-31\n0001053691crvo:May2025AtthemarketOfferingMember2025-01-012025-12-31\n0001053691crvo:May2025AtthemarketOfferingMember2025-05-12\n0001053691crvo:SeriesACommonStockWarrantsMember2026-03-31\n0001053691crvo:HistoricalEIPCommonStockWarrantsMember2026-03-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2025-12-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2026-01-012026-01-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2025-01-012025-03-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2026-01-012026-03-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2026-03-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2025-01-012025-12-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2024-01-012024-12-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2023-01-012023-12-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2024-08-31\n0001053691crvo:NationalInstituteOfAgingGrantMember2023-01-31\n0001053691crvo:VertexOptionAndLicenseAgreementMember2025-01-012025-03-31\n0001053691crvo:VertexOptionAndLicenseAgreementMember2026-01-012026-03-31\n0001053691crvo:VertexOptionAndLicenseAgreementMember2014-08-012014-08-31\n0001053691crvo:VertexOptionAndLicenseAgreementMember2014-08-31\n0001053691us-gaap:USTreasurySecuritiesMember2025-12-31\n0001053691us-gaap:USTreasuryBondSecuritiesMember2025-12-31\n0001053691us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-12-31\n0001053691us-gaap:USTreasurySecuritiesMember2026-03-31\n0001053691us-gaap:USTreasuryBondSecuritiesMember2026-03-31\n0001053691us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-12-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2026-03-31\n0001053691us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2026-03-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001053691us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001053691us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001053691us-gaap:ConvertiblePreferredStockMember2025-01-012025-03-31\n0001053691us-gaap:ConvertiblePreferredStockMember2026-01-012026-03-31\n00010536912025-03-31\n00010536912024-12-31\n0001053691us-gaap:RetainedEarningsMember2025-03-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001053691us-gaap:CommonStockMember2025-03-31\n0001053691us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001053691us-gaap:CommonStockMember2025-01-012025-03-31\n0001053691us-gaap:RetainedEarningsMember2024-12-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001053691us-gaap:CommonStockMember2024-12-31\n0001053691us-gaap:RetainedEarningsMember2026-03-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001053691us-gaap:CommonStockMember2026-03-31\n0001053691us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001053691us-gaap:CommonStockMember2026-01-012026-03-31\n0001053691us-gaap:RetainedEarningsMember2025-12-31\n0001053691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31\n0001053691us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001053691us-gaap:CommonStockMember2025-12-31\n0001053691us-gaap:SeriesAPreferredStockMember2025-12-31\n0001053691us-gaap:SeriesAPreferredStockMember2026-03-31\n00010536912026-05-06\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C.**  **20549**\n\n \n\n**FORM 10-Q**\n\n(Mark one)\n\n \n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n \n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from ___________ to ______________.\n\n \n\n**Commission file number: 001-37942**\n\n \n\n \n\n**CervoMed Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n**30-0645032**\n\n(State or other jurisdiction of incorporation or organization)\n\n(I.R.S. Employer Identification No.)\n\n \n\n**20 Park Plaza, Suite 424**\n\n \n\n**Boston, Massachusetts**\n\n**02116**\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\n**(617) 744-4400**\n\n(Registrant’s telephone number including area code)\n\n \n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title of each class**\n\n**Trading Symbol(s)**\n\n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.001 per share\n\nCRVO\n\nNASDAQ Capital Market\n\n \n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒  No  ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒  No  ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer ☐\n\nAccelerated filer ☐\n\nNon-accelerated filer ☒\n\nSmaller reporting company ☒\n\n \n\nEmerging growth company ☐\n\n \n\n         If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐   No ☒\n\n \n\nThe number of shares of common stock outstanding at May [6], 2026 was [9,258,719] shares.\n\n \n\n \n\n \n\n \n\n  \n\n \n\n**CervoMed Inc.**\n\n \n \n\nPage No.\n\nPart I\n\nPART I – FINANCIAL INFORMATION\n\n1"}